These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 10770741)
1. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Martínez MA; Cabana M; Parera M; Gutierrez A; Esté JA; Clotet B Antimicrob Agents Chemother; 2000 May; 44(5):1132-9. PubMed ID: 10770741 [TBL] [Abstract][Full Text] [Related]
2. Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O. Rodés B; Poveda E; Soriano V J Clin Microbiol; 2002 Nov; 40(11):4313-6. PubMed ID: 12409418 [TBL] [Abstract][Full Text] [Related]
3. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. Iga M; Matsuda Z; Okayama A; Sugiura W; Hashida S; Morishita K; Nagai Y; Tsubouchi H J Virol Methods; 2002 Oct; 106(1):25-37. PubMed ID: 12367727 [TBL] [Abstract][Full Text] [Related]
4. Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. Cabana M; Fernàndez G; Parera M; Clotet B; Martínez MA Virology; 2002 Aug; 300(1):71-8. PubMed ID: 12202207 [TBL] [Abstract][Full Text] [Related]
5. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574 [TBL] [Abstract][Full Text] [Related]
6. A genetic screen for the isolation and characterization of site-specific proteases. Sices HJ; Kristie TM Proc Natl Acad Sci U S A; 1998 Mar; 95(6):2828-33. PubMed ID: 9501175 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. Maschera B; Darby G; Palú G; Wright LL; Tisdale M; Myers R; Blair ED; Furfine ES J Biol Chem; 1996 Dec; 271(52):33231-5. PubMed ID: 8969180 [TBL] [Abstract][Full Text] [Related]
8. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Velazquez-Campoy A; Vega S; Freire E Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278 [TBL] [Abstract][Full Text] [Related]
9. Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Martinez MA; Clotet B Antimicrob Agents Chemother; 2003 May; 47(5):1760-5. PubMed ID: 12709356 [TBL] [Abstract][Full Text] [Related]
10. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514 [TBL] [Abstract][Full Text] [Related]
11. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease. Parera M; Clotet B; Martinez MA J Virol; 2004 Dec; 78(24):14057-61. PubMed ID: 15564515 [TBL] [Abstract][Full Text] [Related]
12. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Patick AK; Boritzki TJ; Bloom LA Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041 [TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685 [TBL] [Abstract][Full Text] [Related]
14. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850 [TBL] [Abstract][Full Text] [Related]
15. Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease. Sices HJ; Leusink MD; Pacheco A; Kristie TM AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1249-55. PubMed ID: 11559424 [TBL] [Abstract][Full Text] [Related]
16. Analysis of recombinant protein toxicity in E. coli through a phage lambda-based genetic screening system. Fernández G; Vera A; Villaverde A; Martínez MA Biotechnol Lett; 2007 Sep; 29(9):1381-6. PubMed ID: 17479218 [TBL] [Abstract][Full Text] [Related]
17. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089 [TBL] [Abstract][Full Text] [Related]
18. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness. Capel E; Martrus G; Parera M; Clotet B; Martínez MA J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665 [TBL] [Abstract][Full Text] [Related]
19. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735 [TBL] [Abstract][Full Text] [Related]
20. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli. Dautin N; Karimova G; Ullmann A; Ladant D J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]